ARTIVA BIOTHERAPEUTICS INC

ARTVNASDAQ

🏆 #3265 by market capUS Equity

$735.61▲ $57.82 (+7.86%)

Simulated price

🔔

Track ARTV

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 7.9%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$344M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Fair

No chart data available for ARTV.

Trading Snapshot

Day Range: $732.10 – $749.34
52-Week Range: $2.71 – $14.53
Volume: $3.11B
Avg Volume: $3.28B
Shares Outstanding: 48.6M
Next Earnings: Dec 7, 2026

Fundamentals Snapshot

Annual Revenue: $43M
Last Q Revenue: $10M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-3.43
Dividend Yield: —
Dilution (1yr): +0.3%

Why Investors Own ARTV

✓High-growth profile — revenue up +6.8% YoY with expanding US Equity exposure.
✓Healthy economics — 32% gross margin and 18% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ARTIVA BIOTHERAPEUTICS INC

ARTV

Financial Trends

Revenue

$0▼ −100.0% YoY

Gross Margin

100.0%▲ +0.0% YoY

Operating Income

−$91M▲ +34.7% YoY

Free Cash Flow

−$79M▲ +42.5% YoY

Shares Outstanding

24.4M▲ +0.3% YoY

Net Cash

$16M▼ −$10M YoY

StockOtter · stockotter.space

About ARTIVA BIOTHERAPEUTICS INC

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.

🦦